ストックスクリーナーアプリを入手
25.91
1.93%
0.49
前日終値:
$25.42
開ける：
$25.58
24時間の取引高:
1.73M
Relative Volume:
1.00
時価総額：
$5.22B
収益：
-
当期純損益:
$-382.71M
株価収益率:
-9.8893
EPS:
-2.62
ネットキャッシュフロー:
$-325.64M
1週間 パフォーマンス:
-0.96%
1か月 パフォーマンス:
+17.67%
6か月 パフォーマンス:
+54.13%
1年 パフォーマンス:
+2.86%
1日の値動き範囲:
$25.48
$26.62
1週間の範囲:
$24.95
$26.62
52週間の値動き範囲:
$12.72
$27.69
Immunovant Inc Stock (IMVT) Company Profile
IMVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.91 | 5.12B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-14 | 開始されました | Truist | Hold |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-03-03 | 開始されました | Jefferies | Hold |
| 2025-01-03 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-09 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2024-03-13 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | JP Morgan | Overweight |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-13 | アップグレード | UBS | Neutral → Buy |
| 2023-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 開始されました | BofA Securities | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-31 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2023-02-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2021-08-03 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-01 | ダウングレード | Stifel | Buy → Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-12 | 開始されました | Guggenheim | Buy |
| 2020-10-08 | 開始されました | Stifel | Buy |
| 2020-10-02 | 開始されました | Credit Suisse | Outperform |
| 2020-08-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Immunovant Inc (IMVT) 最新ニュース
Wolfe Research Downgrades Immunovant (IMVT) - MSN
(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Nasdaq Today Immunology Innovation - Kalkine Media
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution - Sahm
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT - MarketBeat
Research Analysts Issue Forecasts for Immunovant Q3 Earnings - MarketBeat
Momentum Shift: How Immunovant Inc. stock responds to policy changesChart Signals & Consistent Income Trade Recommendations - Улправда
How Immunovant Inc. stock compares to growth peers2025 Top Gainers & Technical Confirmation Alerts - Улправда
Squarepoint Ops LLC Has $1.36 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
How Immunovant Inc. stock responds to policy changesInflation Watch & Long-Term Safe Return Strategies - ulpravda.ru
Tuyl Christopher Van Sells 10,813 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Officer Van Tuyl Acquires 16,676 Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant Executive Sells Shares to Cover Tax Obligations - TradingView — Track All Markets
First Week of IMVT February 2026 Options Trading - Nasdaq
Can Immunovant Inc. stock weather global recessionPortfolio Growth Summary & Low Drawdown Investment Strategies - DonanımHaber
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - AOL.com
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402Has The Bull Case Changed? - Yahoo Finance
The Goldman Sachs Group Forecasts Strong Price Appreciation for Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant SciencesWhat's Changed - Sahm
Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets - ts2.tech
Immunovant (IMVT) down 0.6% since last earnings report: Can it rebound? - MSN
EPS Watch: Why OrthoPediatrics Corp. stock appeals to dividend seekersWeekly Stock Report & Low Drawdown Trading Strategies - moha.gov.vn
Immunovant Raises $550 Million Through Stock Offering - The Globe and Mail
Insider Buying: Sciences Roivant Acquires 16,666,666 Shares of I - GuruFocus
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - MSN
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m By Investing.com - Investing.com Canada
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Roivant Sciences Ltd. Purchases 16.7 Million Immunovant Shares - TradingView — Track All Markets
Owner Roivant Sciences Ltd Buys 16,666,666 ($350M) Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha
Immunovant Enters Underwriting Agreement for Stock Offering - TradingView — Track All Markets
Immunovant (NASDAQ:IMVT) Stock Price Up 8.1%Here's Why - MarketBeat
Immunovant, Inc. $IMVT is Armistice Capital LLC's 9th Largest Position - MarketBeat
Immunovant drops 7%, prices $550M stock offering - MSN
Immunovant announces $550 million stock offering - MSN
Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock - Latham & Watkins LLP
Immunovant announces $550 million stock offering and clinical program updates - Investing.com Canada
Roivant Signals Major Pipeline Momentum With Accelerated Timelines - Sahm
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - MSN
Immunovant Shares Rise After Pricing $550 Million Stock Offering - marketscreener.com
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus - ts2.tech
HighVista Strategies LLC Buys 87,160 Shares of Immunovant, Inc. $IMVT - MarketBeat
Immunovant announces $550 million stock offering and clinical program updates By Investing.com - Investing.com South Africa
Immunovant Announces $550 Million Stock Offering - TipRanks
Immunovant announces pricing of $550 million common stock financing - marketscreener.com
Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView — Track All Markets
Immunovant Prices $550 Million Stock Offering - marketscreener.com
Immunovant Announces Pricing of $550 Million Common Stock Financing - The Globe and Mail
Immunovant Inc (IMVT) 財務データ
収益
当期純利益
現金流量
EPS
Immunovant Inc (IMVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director |
Dec 12 '25 |
Buy |
21.00 |
16,666,666 |
349,999,986 |
113,317,007 |
| Fromkin Andrew J. | Director |
Dec 01 '25 |
Sale |
23.25 |
22,249 |
517,189 |
85,852 |
| Hughes Douglas J. | Director |
Dec 01 '25 |
Sale |
23.24 |
15,000 |
348,665 |
120,773 |
0.57%
大文字化:
|
ボリューム (24 時間):